Regenxbio RGNX Deferred Equity Offering Costs Reclassified
Deferred Equity Offering Costs Reclassified at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:DeferredEquityOfferingCostsReclassified.
The official record: Regenxbio’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regenxbio's deferred equity offering costs reclassified.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regenxbio's deferred equity offering costs reclassified?
- Regenxbio (RGNX) reported deferred equity offering costs reclassified of $124.75K in Q4 2025.
- How has Regenxbio's deferred equity offering costs reclassified changed year-over-year?
- Regenxbio's deferred equity offering costs reclassified decreased by 20.5% year-over-year, from $157K to $124.75K.
- What does deferred equity offering costs reclassified mean?
- This metric represents the reclassification of previously deferred equity issuance costs, typically occurring when the associated equity offering is completed or abandoned. It reflects the accounting adjustment that moves these costs from a deferred asset or liability status to a reduction of equity proceeds or an expense. This is essential for understanding the net proceeds realized from capital market activities.